70 activities found

  • go
  • add

Expert Perspectives: Perspectives in Melanoma XVIII

Drs. John M. Kirkwood and Antoni Ribas summarize the key take-home messages on the latest advances in melanoma research discussed during the Perspectives in Melanoma XVIII Annual Meeting held in Dublin, Ireland. The newest scientific ideas on melanoma genetics and biology, screening and surveillance, BRAF and MEK inhibitor therapy, immunotherapies, and combination strategies are highlighted in a one-on-one dialogue; moreover, global access to novel melanoma drugs and insights on current practice patterns are provided.
  • Audio
  • Video
  • Text
0.5 CME
  • go

Monograph: The Clinical Application of Therapeutic Drug Monitoring to Optimize Anti-TNFa Therapy in IBD: An Interactive Case-Based Approach

The management of inflammatory bowel disease patients has improved with an increased understanding of the factors that influence the inter-individual variability in efficacy and tolerability of anti-tnf therapies. The field is focusing on improving an understanding of the pharmacokinetic and immunogenicity influences on response heterogeneity. As new clinical findings emerge with the potential to impact patient care, it is essential that healthcare providers remain up-to-date in order to make informed treatment decisions for their patients with IBD. This online monograph will provide an interactive update on therapeutic drug monitoring and provide guidance on algorithmic-based approaches to patients losing response to anti-TNF therapies.
  • Audio
  • Video
  • Text
1 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Breast Cancer

In this "Best of the Day" presentation from ESMO 2014, Dr. Javier Cortes reviews the latest advances, clinical trial updates, and late-breaking news presented during this year's Breast Cancer sessions. Highlights include: final overall survival data from the phase III CLEOPATRA trial for patients with HER2 metastatic breast cancer; updates to the phase III IMELDA and TANIA trials, providing an understanding of the benefits of bevacizumab maintenance therapy for patients with HER2-negative metastatic breast cancer; and characterization of breast cancer tumors.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Melanoma

In this "Best of the Day" interview from ESMO 2014, Dr. Axel Grothey is joined by Dr. Caroline Robert to review the latest advances, clinical trial updates, and late-breaking news presented during this year's Melanoma sessions. Discussion highlights include: an overview of anti-PD-1/PD-L1 antibodies approved or in development; emerging therapies for BRAF V600E/K mutation-positive melanoma; and late-breaking updates on the Phase III Co-BRIM trial.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Gastrointestinal Cancer

In this "Best of the Day" interview from ESMO 2014, Dr. Axel Grothey is joined by Dr. Florian Lordick to review the latest advances, clinical trial updates, and late-breaking news presented during this year's GI Malignancies sessions. Discussion highlights include: new and emerging therapies for gastric, pancreatic, and colorectal cancers; immunotherapy for gastrointestinal malignancies; and antiangiogenic agents for advanced gastrointestinal malignancies.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Genitourinary Cancers

In this "Best of the Day" interview from ESMO 2014, Dr. Ramaswamy Govindan is joined by Dr. Cora Sternberg to review the latest advances, clinical trial updates, and late-breaking news presented during this year's Genitourinary Cancer sessions. Discussion highlights include: practice-changing results from the CHAARTED prostate cancer trial; updates on PREVAIL, COUGAR 302, and AFFIRM trials; and an update on androgen receptor splice variant AR-V7's status as a biomarker to predict resistance to androgen receptor targeting agents.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Best of the Day: from the 2014 European Society of Medical Oncology (ESMO) Congress - Lung Cancer

In this "Best of the Day" interview from ESMO 2014, Dr. Axel Grothey is joined by Dr. Ramaswamy Govindan to review the latest advances, clinical trial updates, and late-breaking news presented during this year's Thoracic Oncology sessions. Discussion highlights include: new therapies on the horizon for ALK-positive lung cancer; updates on RADIANT and ALCHEMIST thoracic cancer trials; and updates on the molecular characterization of tumors.
  • Audio
  • Video
  • Text
0 CME
  • go
  • add

Expert Perspectives: US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2014

Filmed at the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2014 meeting, this video discussion between Drs. Srdan Verstovsek, Ruben A. Mesa, Jason R. Gotlib, and Ramon V. Tiu outlines key learning points and summarizes take home messages from the presented content. This engaging conversational format provides expert perspectives on recent discoveries that have the potential to change the paradigm of how MPNs and MDS are diagnosed and treated, and enhance clinical outcomes and quality of life for patients with MPNs and MDS.
  • Audio
  • Video
  • Text
0.5 CME
  • go
  • add

Webcast: Optimizing Clinical Outcomes for Patients with Polycythemia Vera: A Satellite Symposium during Perspectives in MPN and MDS 2014

Polycythemia vera is the most common of the myeloproliferative neoplasms characterized by elevated hematocrit, splenomegaly and increased thrombotic risk. Together these conditions result in significant symptom burden and a reduced quality of life for these patients. The recent identification of genetic variants associated with polycythemia vera have enhanced methods for classification and diagnosis of disease, contributed to more robust risk stratification models and led to the identification of novel targeted therapies for treatment of disease and alleviation of symptom burden. As these advances have the potential to provide significant benefits to patient quality of life and clinical outcomes, clinical challenges pertaining to incorporation of these new methodologies and therapies into everyday clinical practice are coming to light. Therefore, it is imperative that healthcare professionals are kept current of new and emerging clinically relevant findings and how their utilization in the clinical setting can provide optimal care for patients with PV for the enhancement of quality of life and clinical outcomes.
  • Audio
  • Video
  • Text
1 CME
  • go
  • add

Webcast: Clinical Trial Opportunities in Squamous Cell Carcinoma of the Lung

Dr. Mark Socinski highlights the epidemiology and current treatment outcomes of squamous cell carcinoma lung cancer patients and specifically details the effectiveness of different standards of care and emerging novel strategies for patients with squamous histology. He also discusses ongoing clinical trials with potential for benefit in this subset of patients.
  • Audio
  • Video
  • Text
0.5 CME